Microbot Medical (MBOT) Expected to Announce Earnings on Wednesday

Microbot Medical (NASDAQ:MBOT) is anticipated to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect Microbot Medical to post earnings of ($0.08) per share and revenue of $0.01 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Microbot Medical (NASDAQ:MBOT) last posted its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. On average, analysts expect Microbot Medical to post ($0.30) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

Microbot Medical Stock Up 4.8%

Shares of NASDAQ:MBOT opened at $1.09 on Wednesday. Microbot Medical has a 12 month low of $0.93 and a 12 month high of $2.85. The company has a 50-day moving average price of $1.23 and a 200 day moving average price of $1.84.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MBOT. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a research note on Wednesday, October 21st. Citigroup started coverage on Microbot Medical in a report on Friday, October 23rd. They set a “market outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, October 2nd. Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen lowered shares of Microbot Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 24th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $5.08.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians’ exposure to radiation.

The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.